Controversies on the role of Th17 in cancer: A TGF-β-dependent immunosuppressive activity?

Trends in Molecular Medicine

Volumn 18, Issue 12, 2012, Pages 742-749

  Martin, François ^a,b   Apetoh, Lionel ^a,b,c   Ghiringhelli, François ^a,b,c  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Adenosine; Angiogenesis; Ectonucleotidases; Immunosuppression; Plasticity; TGF ; Th17; Tumor immunity

Indexed keywords

5' NUCLEOTIDASE; CD39 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTING CELL; BILE DUCT CANCER; CELL DIFFERENTIATION; COLORECTAL CANCER; ESOPHAGUS CANCER; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; NASOPHARYNX CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW; STOMACH CANCER; TH17 CELL; TUMOR IMMUNITY;

5'-NUCLEOTIDASE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; APYRASE; CELL DIFFERENTIATION; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TH1 CELLS; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84870253748     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.09.007     Document Type: Review

References (85)

1. Mosmann T.R., et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
2. Park H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
3. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
4. Korn T., et al. IL-17 and Th17 cells. Annu. Rev. Immunol. 2009, 27:485-517.
5. Fouser L.A., et al. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol. Rev. 2008, 226:87-102.
6. Ye P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 2001, 194:519-527.
7. Barin J.G., et al. Macrophages participate in IL-17-mediated inflammation. Eur. J. Immunol. 2012, 42:726-736.
8. Tesmer L.A., et al. Th17 cells in human disease. Immunol. Rev. 2008, 223:87-113.
9. + T helper cells. Cell 2006, 126:1121-1133.
10. Bettelli E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
11. Veldhoen M., et al. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
12. McGeachy M.J., et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007, 8:1390-1397.
13. Codarri L., et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12:560-567.
14. El-Behi M., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011, 12:568-575.
15. Ghoreschi K., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature 2010, 467:967-971.
16. Lee Y.K., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009, 30:92-107.
17. Acosta-Rodriguez E.V., et al. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007, 8:942-949.
18. Yang L., et al. IL-21 and TGF-β are required for differentiation of human T(H)17 cells. Nature 2008, 454:350-352.
19. Koenen H.J., et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
20. +Treg in the presence of lineage-specific polarizing factors. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19402-19407.
21. + T helper intermediates display suppressive function against autoimmune diabetes. J. Immunol. 2010, 184:3377-3385.
22. Mukasa R., et al. Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity 2010, 32:616-627.
23. + T cells. Immunity 2009, 30:155-167.
24. Hoechst B., et al. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011, 117:6532-6541.
25. Hu W., et al. Priming microenvironments dictate cytokine requirements for T helper 17 cell lineage commitment. Immunity 2011, 35:1010-1022.
26. Kagami S., et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 2010, 130:1373-1383.
27. Chen D.Y., et al. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res. Ther. 2011, 13:R126.
28. + IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15505-15510.
29. Zhang J.P., et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 2009, 50:980-989.
30. Kesselring R., et al. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br. J. Cancer 2010, 103:1245-1254.
31. + regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci. 2010, 101:1947-1954.
32. Tosolini M., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71:1263-1271.
33. Su X., et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 2010, 184:1630-1641.
34. He S., et al. Distribution and clinical significance of th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int. J. Mol. Sci. 2011, 12:7424-7437.
35. Kuang D.M., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010, 51:154-164.
36. Murugaiyan G., Saha B. Protumor vs antitumor functions of IL-17. J. Immunol. 2009, 183:4169-4175.
37. Ji Y., Zhang W. Th17 cells: positive or negative role in tumor?. Cancer Immunol. Immunother. 2010, 59:979-987.
38. Maniati E., et al. Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 2010, 29:5653-5662.
39. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010, 10:248-256.
40. Wilke C.M., et al. Th17 cells in cancer: help or hindrance?. Carcinogenesis 2011, 32:643-649.
41. Middleton G.W., et al. Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?. Cancer Immunol. Immunother. 2012, 61:1-7.
42. Kryczek I., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
43. Zhu X., et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008, 10:R95.
44. Zhang Y.L., et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol. Cancer 2010, 9:4.
45. Wang L., et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009, 206:1457-1464.
46. Kryczek I., et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359.
47. Muranski P., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
48. Muranski P., et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011, 35:972-985.
49. Nurieva R., et al. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J. Immunol. 2009, 182:2565-2568.
50. Martin-Orozco N., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
51. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
52. Folkman J. Angiogenesis. Annu. Rev. Med. 2006, 57:1-18.
53. Numasaki M., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627.
54. Tong Z., et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS ONE 2012, 7:e34959.
55. Weber G.F., et al. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J. Immunol. 2006, 177:8266-8272.
56. Castermans K., et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood 2008, 112:4940-4947.
57. Chauhan S.K., et al. A novel pro-lymphangiogenic function for Th17/IL-17. Blood 2011, 118:4630-4634.
58. + Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol. Rep. 2011, 25:1271-1277.
59. Liu J., et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem. Biophys. Res. Commun. 2011, 407:348-354.
60. + T cells with potent suppressive function. Eur. J. Immunol. 2011, 41:936-951.
61. Annunziato F., Romagnani S. The transient nature of the Th17 phenotype. Eur. J. Immunol. 2010, 40:3312-3316.
62. Chalmin F., et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012, 36:362-373.
63. Deaglio S., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204:1257-1265.
64. + cells. J. Immunol. 2011, 187:6120-6129.
65. Regateiro F.S., et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β. Eur. J. Immunol. 2011, 41:2955-2965.
66. Stagg J., Smyth M.J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010, 29:5346-5358.
67. Kurschus F.C., et al. Genetic proof for the transient nature of the Th17 phenotype. Eur. J. Immunol. 2010, 40:3336-3346.
68. Derynck R., et al. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985, 316:701-705.
69. Annunziato F., et al. Human Th17 cells: are they different from murine Th17 cells?. Eur. J. Immunol. 2009, 39:637-640.
70. Annunziato F., Romagnani S. Mouse T helper 17 phenotype: not so different than in man after all. Cytokine 2011, 56:112-115.
71. Racz E., et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J. Invest. Dermatol. 2011, 131:1547-1558.
72. Huh J.R., et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 2011, 472:486-490.
73. Roark C.L., et al. γδ T cells: an important source of IL-17. Curr. Opin. Immunol. 2008, 20:353-357.
74. Wakita D., et al. Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 2010, 40:1927-1937.
75. Ma Y., et al. Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 2011, 208:491-503.
76. Garcia-Hernandez M.L., et al. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J. Immunol. 2010, 184:4215-4227.
77. + T cells display enhanced antitumor immunity. Blood 2009, 114:596-599.
78. Michel M.L., et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J. Exp. Med. 2007, 204:995-1001.
79. Dong C. Genetic controls of Th17 cell differentiation and plasticity. Exp. Mol. Med. 2011, 43:1-6.
80. Cohen C.J., et al. Human Th1 and Th17 cells exhibit epigenetic stability at signature cytokine and transcription factor loci. J. Immunol. 2011, 187:5615-5626.
81. + memory stem cells. Nat. Med. 2009, 15:808-813.
82. Chen X., et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010, 69:348-354.
83. Lv L., et al. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS ONE 2011, 6:e18219.
84. Chen J.G., et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int. J. Biol. Sci. 2011, 7:53-60.
85. + T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int. J. Cancer 2009, 125:1372-1379.